

This listing of claims will replace all prior versions, and listings, of claims in the application.


Listing of Claims:

1. (Cancelled).

2. (Cancelled).

3. (Cancelled).

4. (Currently amended) The A serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis ~~according to claim 1 wherein the~~ comprising a combination of a compound represented by the ~~above mentioned~~ following general formula (I) ~~is the following formula~~ or its pharmaceutically acceptable salts



and at least one HMG-CoA reductase inhibitor.

5-28. (Cancelled).


29. (New) The serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to claim 4, wherein the HMG-CoA reductase inhibitor is selected from the group consisting of pravastatin, lovastatin, fluvastatin, simvastatin, itavastatin, atorvastatin, cerivastatin, rosuvastatin, pitavastatin and carvastatin.

30. (New) The serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to claim 4 administered in a manner chosen from the group consisting of a powder, tablet, granule, capsule, liquid, suspension, suppository, ointment and inhalant.

31. (New) The serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to claim 4 further comprising one or more pharmaceutically acceptable additives or excipients selected from the group consisting of lubricants, binders, collapses, fillers, buffers, emulsifiers, preservatives, anti-oxidants, coloring agents, coating agents and suspending agents.


32. (New) The serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to claim 4

administered in amounts corresponding to 0.1~100 mg/kg (mammalian weight) per day in divisions of the compound represented by the general formula



and 5~100 mg/kg (mammalian weight) per day in divisions of the HMG-CoA reductase inhibitor.

33. (New) The serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to claim 4 wherein the compound represented by the general formula



and the HMG-CoA reductase inhibitor are administered simultaneously or consecutively.